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1. Introduction 
Pregnancy is physiologically characterized by an increased procoagulant activity; in fact, 
pregnant women have two- to fivefold higher risk for venous thromboembolism compared 
with nonpregnant women (Grandone et al., 1998). Coagulation factors VII, X, VIII, 
fibrinogen, von Willebrand factor, prothrombin fragment 1 and 2, and thrombin–
antithrombin complexes increase (Bremme, 2003). In parallel, there is a decrease of 
physiologic anticoagulants such as protein S and the acquisition of activated protein C 
resistance. These physiologic changes appear to relate to the development of an adequate 
placental perfusion and provide a protective mechanism for hemostasis during delivery. A 
hypercoagulable state may expose, however, the pregnant women to thrombotic risk during 
pregnancy and the immediate postpartum period. This risk is higher in women with 
multiple thrombophilic defects (Tranquilli et al., 2004). Congenital thrombophilia includes 
deficiency or defects of some factors such as antithrombin, protein C and S, and in the case 
of genetic specific mutations of one or more genes among these indicated: 
methylenetetrahydrofolate reductase (MTHFR C677 T), Prothrombin (FII G20210A), Factor 
V (FV G1691A), and Plasminogen activator inhibitor-1 (PAI-1 4G/5G). In the literature, 
thrombophilia has been reported as related to obstetric pathology; in particular, the 
association with intrauterine fetal death (IUFD), a complication that ranged from 4.9 to 10.4 
babies in each 1,000, and where in the 12% to 50% of cases the cause remains unknown, has 
been confirmed (Martinelli et al., 2003;  Kupferminc et al., 1999; Preston et al. 1996) or not 
confirmed (Gonen et al., 2005). Although thrombophilia is extensively studied for its 
implications in pregnancy complications, the role of different factors, the gestational age at 
which those factors may intervene, has not been completely elucidated, nor has it been 
given enough relevance to the weight of fetal thrombophilia in the origin of some specific 
form of those obstetric complications (Tranquilli et al., 2006). Most of the actual studies in 
the literature have focused their attention on maternal biologic samples and considering 
exclusively the genetic contribution of the mother. 
2. Placental genetics and biology 
The placenta is the highly specialised organ of pregnancy that supports the normal growth 
and development of the fetus. Changes in placental development and function have 
dramatic effects on the fetus and its ability to cope with the  intrauterine environment. 
Implantation and the formation of the placenta is a highly coordinated process involving 
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interaction between maternal and embryonic cells. Trophoblast cell invasion of uterine 
tissues and remodelling of uterine spiral arterial walls ensures that the developing feto-
placental unit receives the necessary supply of blood and that efficient transfer of nutrients 
and gases and the removal of wastes can take place. Different types of placentation are 
categorised according to the number and types of layers between the maternal and fetal 
circulations, the human placenta is defined as a “haemochorial” villous organ,  In the 
hemochorial placentation the wall of maternal blood vessels going towards the implantation 
site is breached and maternal blood bathes placental cells. In this process, maternal blood 
passes through channels that are lined by placental trophoblast cells (Georgiades et al., 
2002). This situation contrasts with all other vascular beds where the blood vessel 
endothelium lies at the blood tissue interface. The human trophoblast cells express a range 
of gene products that are expressed normally by the endothelium and that regulate the 
hemostatic function. These include molecules that regulate thrombin activity 
(thrombomodulin, endothelial protein C receptor, tissue factor pathway inhibitor), 
regulators of vasodilation and platelet function (nitric oxide synthase 2, cyclooxygenase 2 
and prostacyclin synthase) and some regulators of fibrinolysis (plasminogen activator 
inhibitor, tissue plasminogen activator). These findings suggest that, although derived from 
a distinct developmental lineage, trophoblast cells mimic endothelial cells in their ability to 
partake in anticoagulant and fibrinolytic activities. Trophoblast cells are derived from the 
zygote and are genetically identical to the fetus (Sood, 2009). The development of gene 
“knock-out” and transgenic animal models indicate that complete absence of  tissue factor, 
tissue factor pathway inhibitor or prothrombin is lethal in the developing mouse embryo. 
Placental thrombi resulting in placental infarction may also occur on either side of the 
maternal-fetal interface and may have serious implications for the mother or her fetus, 
including an increased risk for perinatal morbidity and mortality (Fuke et al., 1994;  Redline 
et al., 1995). A placental infarct is an area of placental parenchyma that has undergone 
ischemic necrosis; it may occur on either side of the maternal-fetal interface. Development of 
the fetal arterial blood supply to the placenta begins as early as 18 to 20 days after 
conception. The fetal placental vessels vary little from vessels of other organs and are lined 
by endothelial cells. Endothelium-lined vessels are dependent on the normal balance of 
procoagulant and anticoagulant mechanisms for damage repair and maintaining blood 
fluidity. Failure to maintain this delicate balance in the presence of a fetal hypercoagulable 
state may result in placental infarction in the distribution of fetal vessels and may even 
result in early spontaneous miscarriage. Furthermore placental infarction is more common 
in women with severe preeclampsia (Salafia et al., 1995) but it is not known whether it 
precedes the onset of disease or develops as a consequence. Because vascular features of the 
placenta seem to be involved, and because the placenta is of fetal origin, fetal genes related 
to vascular conditions could be relevant. In cases of maternal thrombophilia associated with 
fetal growth restriction (FGR), maternal floor infarction of the placenta, which is 
characterized by deposition of fibrinoid material, could be found not only in the maternal 
surface but also in intervillous spaces of the placenta (Adams-Chapman et al., 2002). Thus, 
both maternal thrombophilia and infarction of intervillous spaces of the placenta could be 
causes of fetal growth restriction. Antiphospholipid antibodies syndrome (APS) represents a 
singular case of maternal and fetal thrombophilia since the antiphospholipid antibodies 
cross the placental wall. The hypothesis that hypercoagulability of APS was in some way 
impacting the utero-placental circulation is supported by the finding of intervillous 
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thrombosis, extensive villous fibrosis, or rather marked infarction in some placentas of APS 
pregnancies. Numerous possible mechanisms of thrombosis in the intervillous space have 
been considered such as increased tissue factor (Branch et al., 1993;  Dobado-Berrios et al., 
1999) or prostacyclin-thromboxane pathway (Peaceman et al., 1993). If the thrombotic 
tendency may explain the later placental insufficiency, a particularly attractive candidate 
mechanism for early pregnancy loss as well as placental insufficiency in later pregnancy is 
aPL-mediated inhibition of trophoblast invasion (Di Simone et al., 2000). 
3. Fetal and neonatal genetics 
Despite the number of studies that have confirmed or not confirmed an association between 
inherited thrombophilias and pregnancy complications, it remains difficult to establish the 
exact risk figures for particular adverse events in the presence of genetic thrombophilic 
mutations. The complexity of the placental disorders of pregnancy has led more Authors to 
speculate that a feto-maternal genome interaction is plausible (Lie et al., 1998). When the 
fetus itself has an inherited risk of thrombosis, pregnancy is also more prone to placental 
infarction at the maternal–fetal interface resulting in an increased risk for intrauterine death 
as compared with fetuses from uncomplicated pregnancies. This is consistent with the 
observation that women who are homozygous of factor V Leiden mutation, an inherited risk 
for thrombosis, are even more prone to fetal loss (Meinardi et al., 1999). A higher prevalence 
of fetal genetic risk factors for thrombosis (factor V Leiden or prothrombin 20210A allele) 
was found in fetuses born from a pregnancy complicated with intrauterine fetal death as 
compared with the prevalence of a historic control group (Dekker et al., 2004). It has been 
speculated that the Factor V Leiden mutation could contribute to the development of 
obstetric complications by promoting the formation of microthrombi in the placenta, thus 
compromising fetomaternal circulation (Younis et al., 1997). By the results of Tranquilli et al. 
(Tranquilli et al. 2010) no higher risk was observed when a singular gene mutation occurs. 
On the contrary, the mutation of Factor V is significantly more frequent when an 
intrauterine fetal demise occurs. The results obtained by the PAI-1 and MTHFR gene 
analysis are particularly interesting because was observed a cumulative higher risk for 
intrauterine fetal demise when a double condition of homozigosity occurs relative to the two 
genes, according to other investigators (Alonso et al., 2002; Pickering et al., 2001). The 
association between homozygosity for polymorphism of MTHFR and PAI-1 with the 
thrombotic phenomenons is controversial, but seem to be in accord with Nelen et al. (Nelen 
et al., 1997), who described the double condition of homozygosity MTHFRT/Tand PAI-1 4 
G/4 G as a cause contributing to the pregnancy loss. The common mutation analyzed in the 
MTHFR gene has been reported to reduce the enzymatic activity. This variant is responsible 
of elevated plasmatic levels of homocysteine mainly after an oral load of methionine: the 
condition of homozygosity for MTHFR T/T predisposes to the onset of blood 
hyperomocisteine (Jacques et al., 1996). PAI-1 is the main factor of the regulation of the 
Plasminogen activators, and homozigosity for PAI 4 G/4 G is associated with increased 
PAI-1 levels and decrease fibrinolitic activity, which lead to a reduction of the trophoblast’s 
ability to invade into the endometrium and compromise the successful placentation. The 
underling hypothesis is that thrombophilia mediated by the physiologic hyperestrogenemia 
of pregnancy may be synergistic, with a genetic thrombophilic pattern promoting thrombus 
formation in the spiral arteries of the placenta, placental insufficiency, and pregnancy loss 
(Paidas et al., 2004). Jivraj et al. (16) reported that only multiple thrombophilic mutations in 
either partner of recurrent miscarriage couples increased the risk of miscarriages in 
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subsequent pregnancies 1.9-fold. Evidence suggests that preeclampsia has a maternal 
genetic component. Preeclampsia is more common in mothers, daughters, and sisters of 
women who experience preeclampsia, suggesting a role of inherited susceptibility of 
preeclampsia through maternal genes (Lie et al., 1998). Men who have fathered one 
preeclamptic pregnancy are nearly twice as likely to father a preeclamptic pregnancy in a 
different woman (Lie et al., 1998). Fathers who themselves came from a preeclamptic 
pregnancy are also at increased risk of fathering a preeclamptic pregnancy (Esplin et al., 
2001). Numerous casecontrol studies of affected and unaffected mothers indicate an 
association between genes expressing thrombophilia and genes expressing preeclampsia 
(Powers et al., 1999; van Pampus et al., 1999;  Kupferminc et al., 2000;  Kim et al., 2001), but 
none of the 27 such studies covered in a recent review (Alfirevic et al., 2002) assessed or 
adjusted for possible effects of fetal alleles. In fact compared with controls, preeclamptic 
women from 16 studies were more heterozygous for the FVL (RR=1.6; CI=1.2 to 2.1) or 
homozygous for the MTHFR variant (RR=1.7; CI=1.2 to 2.3) Because mothers with variant 
alleles also more often have children with variant alleles, adjustment for fetal alleles could 
be essential for correct estimation of the effects of maternal alleles (Vefring et al., 2004). 
Small case series suggest concordance for preeclampsia in identical twins (Lachmeijer et al., 
1998; O’Shaughnessey et al., 2000), but a large cohort study found no evidence of 
concordance (Thornton & Macdonald, 1999). Thus, it is clear that maternal genes alone do 
not determine the risk. Changing paternity, and thus changing maternal–paternal genomic 
expression in the fetus, is associated with an increased risk of preeclampsia (Lie et al., 1998). 
Kajantie et al. reported that people born after pregnancies complicated by preeclampsia are 
at increased risk of stroke in adult life (Kajantie et al., 2009). Fetal thrombophilia may result 
from low birth weight. In a retrospective analysis, von-Kries and colleagues (Von-Kries et 
al., 2001) stated that a higher odds ratio for birth weight in the lowest quartile was observed 
among children carrying prothrombotic risk factors. This conclusion was not supported by 
Rivard and colleagues (Infante-Rivard et al., 2002) in a large case-controlled study. The 
placenta, which has its own hemostatic mechanisms, is probably an important locus of 
pathology in perinatal arterial ischemic stroke (PAS). Association between thrombosis and 
infarction in the placenta and peri- and neonatal infarction, the most commonly presumed 
mechanism being embolization to the fetus, has been reported in literature (Adams-
Chapman et al., 2002). Pregnancy itself is a prothrombotic state as shift toward 
prothrombotic reactions is seen in women as gestation progresses through the second and 
third trimesters and just after gestation (Clark et al., 2003). In cases reviewed for litigation 
because of cerebral palsy in the child, thrombotic lesions were the most common pathology 
found in the placenta (Kraus et al., 1999).  In a study in a national inpatient sample (James et 
al., 2005)  reported risk factors for pregnancy-related stroke to include postnatally identified 
infection (OR 25); migraine (OR 16.9); thrombophilia, including history of thrombosis and 
the antiphospholipid syndrome (OR 16.0); systemic lupus (OR 15.2); heart disease (OR 13.2); 
preeclampsia (OR 4.4); diabetes (OR 2.5); and smoking (OR 1.9). A number of reports 
describe acquired thrombophilias in women whose pregnancies resulted in the birth of a 
child with perinatal stroke (Nelson, 2007). Antiphospholipid antibodies can pass from 
mother to child via the placenta and can alter the placenta itself, changing its function. In 
one of the few studies limited to perinatal arterial ischemic stroke, Gunther and colleagues 
(Gunther et al., 2000)  found at least 1 of the 6 examined prothrombotic risk factors in 68% of 
affected children and in 24% of controls. Factor V Leiden mutation, the prothrombin 
mutation, hyperhomocystinemia, and elevated lipoprotein (a) levels have been described 
with increased frequency in infants who have PAS when compared with healthy control 
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subjects (Hogeveen et al., 2003; Golomb, 2003)  . In a cohort study from the UK of Mercuri 
and coll. (Mercuri et al., 2001). among 24 infants with perinatal cerebral infarction confirmed 
by neonatal magnetic resonance imaging, 10 (42%) had at least one prothrombotic risk 
factor. There are some reports on an increased incidence of thrombophilic risk factors in 
selective cohorts of neonates who have vascular complications, such as intraventricular 
hemorrhage (Pet et al., 2001), retinopathy of prematurity, and necrotizing enterocolitis. 
Hypercoagulability may also be associated with late neurologic sequelae (Smith et al., 1976). 
Necrotizing enterocolitis (NEC) is associated to hematologic abnormalities, including 
evidence for intravascular coagulation (Hutter et al., 1976). Nonetheless, whether 
thrombophilic risk factors promote the occurrence of NEC or its severity remains to be 
proven (Kenet et al., 2006). Furthermore, neonatal posthemorrhagic ventriculomegaly, 
following fetal germinal matrix-intraventricular hemorrhage (GMH-IVH) diagnosed in 
utero by means of NMR, was recently described in a neonate found to be heterozygous for 
two thrombophilic patterns, factor V Leiden and methylenetetrahydrofolate reductase 
mutation (Ramenghi et al., 2005). The possible pathogenesis of intraventricular hemorrhage 
(IVH)may be vessel occlusion triggering high-pressure bleeding. The incidence of Factor V 
of Leiden was increased among infants reported in two case-series with IVH and as 
hydrocephalus (Aronis et al., 1998); however, the occurrence of periventricular leukomalacia 
(PVL) in patients who had IVH was not increased among FVL-heterozygous patients 
(Aronis et al., 1998). In a series of 29 cases Redline and Pappin demonstrated that neonatal 
death, intrauterine growth restriction, birth asphyxia, major thrombotic events and 
thrombocytopenia were the major neonatal complications associated with avascular villi 
(Redline et al., 1995). Retinopathy of prematurity (ROP) is considered as a multifactorial 
disease and was reported to be associated with hypoxia-induced angiogenesis. Since 
vasculogenesis may be influenced by the presence of thrombophilic risk factors Kenet et al. 
(Kenet et al., 2003) studied the incidence and severity of ROP was similar among premature 
infants who had thrombophilia as compared with nonthrombophilic infants of the study 
group. The prevalence of genetic prothrombotic markers (FVL, MTHFR, FII20210A) and 
plasma omocysteine levels were assayed in 166 premature and low-birth-weight infants but 
the prevalence of perinatal complications and the severity of diseases were similar among 
infants with or without thrombophilia, although the numbers of patients within any 
subgroup of complications was small.  
4. Therapy 
A successful pregnancy requires the development of adequate placental circulation, 
thrombophilia may be hypothesised to be a risk factor for the placenta mediated pregnancy 
complications and anticoagulants (heparin and aspirin) may be of interest to prevent these 
complications. In clinical trials the effects of some of these drugs on the development of 
preeclampsia have already been investigated in pregnant women. Low-molecular-weight 
heparins, fractions of crude heparin with high bioavailability and a relatively long half-life, 
are produced by the enzymatic or chemical breakdown of unfractionated heparin and have 
been widely used during the last decade. It has been shown that they do not cross the 
human placenta in vivo. Two general hypotheses have been proposed to explain how 
heparin and aspirin attenuate miscarriage rates: The first involves prevention of aberrant 
coagulation, reducing placental ischemia and the second involves direct modulation of cell 
biology, preventing apoptosis and maintaining trophoblast proliferation (Yacobi et al., 
2002). Since the aspirin cross the placental wall its effect may act also on the fetal side. In 
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randomized placebo-controlled studies, administration of aspirin throughout the first 
trimester, but not later than 16 weeks, or of LMWH starting at 10-11 weeks of gestation or 
even before conception, lowered the risk of developing hypertensive disorders and 
intrauterine growth restriction in pregnancy (Rey et al., 2009; Duley et al., 2007). The 
potential effect of aspirin in improving pregnancy outcomes is due to the selective inhibition 
of thromboxane synthesis without impairing prostacyclin synthesis. However the placenta 
effect of aspirin can vary between individuals because liver metabolism, adding a reason to 
the why aspirin may not be good for all patients. The interplay between the coagulation 
system and the placenta mediated pregnancy complications may not be isolated to 
thrombotic effects at a vascular level leading to placental insufficiency. Recent evidence 
demonstrates that coagulation activation may directly impact on trophoblast cell growth 
and differentiation at a cellular level without thrombosis at a vascular level as an 
intermediary. That is, coagulation activation may play a role in the development of placental 
insufficiency through abnormal placental development rather than placental vascular 
thrombosis. The anticoagulant activity of heparin is mediated by both antithrombin 
dependent and independent pathways, but the role of heparin as an anti-inflammatory 
agent has been the subject of much investigation. Inflammation is known to play a key role 
in pathogenesis of preeclampsia and other obstetric complications. The immunological 
mechanism involves the regulation of Th1/ Th2 balance, production of inflammatory 
cytokines and leuckocyte activation. Animal models have shown that heparin disacchrides 
inhibit TNF α production by macrophages, and hence decrease immune mediated 
inflammation (Tyrell et al., 1995). The anti inflammatory effect is mediated by antithrombin 
and a TFPI independent pathway, by inhibition of matrix degrading enzymes, proteases and 
also by Selectin modulation. Mello et al. reported that the absolute risk of pre-eclampsia was 
reduced from 28.2% (11/39) in the no drug intervention group to 7.3% (3/41) in the 
dalteparin group. The absolute risk of early onset preeclampsia (≤34 weeks gestation) was 
similarly reduced from 20.5% (8/39) in the no drug intervention group to 2.4% (1/41) as was 
fetal growth restriction from 43.6% (17/39) in the no drug intervention group to 9.8% (4/41) 
in the dalteparin group (Mello et al., 2005). Further prospective studies are needed to assess 
whether inherited or acquired thrombophilia increases the risk of development and 
recurrence Placental mediated disorders of pregnancy. The administration of prophilactic 
doses of low–molecular weight heparin from the beginning of pregnancy may reduce the 
recurrence rate of these disorders. If the use of antithrombotic therapy will be proven to be 
effective in reducing maternal and perinatal morbidity and mortality, acceptable, and cost 
effective, then a screening program should be planned to identify women and fetus with 
thrombophilia and a past history of severe complications of pregnancy. 
5. Conclusions 
Inherited and acquired factors may determine thrombophilia. Given that some 
complications of pregnancy are not always associated with maternal thrombophilia, 
controversy still exists on the exact impact of the disorders with the adverse pregnancy 
outcomes. While we are convinced that thrombophilias are extensively implicated in 
pregnancy complications, we feel that there has not been completely elucidated the role of 
the different factors, the gestational age at which those factors may intervene, nor has been 
given enough relevance to the weight of fetal thrombophilias in the origin of some specific 
form of those obstetric complications. The homozygosity of polymorphism in placental 
tissue necessarily includes a role of the father’s genetic pattern in pregnancy destiny, and 
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may identify a ‘‘fetal thrombophilic status’’ inherited from both parents. Maternal 
thrombophilias may be responsible for venous thromboembolism, preeclampsia HELLP 
syndrome and eclampsia, whereas fetal thrombophilia, may account for fetal growth 
restriction or stillbirth. This last would also explain some stillbirth or repeated late 
miscarriage observed in non-thrombophilic mothers. The two sides of thrombophilia may, 
of course, concur, resulting in the more severe clinical presentations. The clinical 
implications of these hypothesis need to be addressed in future research to answer the 
question of whether or not maternal/paternal/fetal thrombophilia should be treated with 
low molecular-weight heparin and/or low dose aspirin. 
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